Published in Clin Infect Dis on February 07, 2002
Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis (2009) 5.75
The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med (2011) 4.91
Association of diabetes and tuberculosis: impact on treatment and post-treatment outcomes. Thorax (2012) 2.39
Impact of diabetes mellitus on treatment outcomes of patients with active tuberculosis. Am J Trop Med Hyg (2009) 2.30
Type 2 diabetes and tuberculosis in a dynamic bi-national border population. Epidemiol Infect (2006) 2.09
Convergence of the tuberculosis and diabetes epidemics: renewal of old acquaintances. Clin Infect Dis (2007) 1.63
Fluoroquinolone exposure prior to tuberculosis diagnosis is associated with an increased risk of death. Int J Tuberc Lung Dis (2012) 1.58
Association between tuberculosis and diabetes in the Mexican border and non-border regions of Texas. Am J Trop Med Hyg (2006) 1.53
Diabetes mellitus and tuberculosis facts and controversies. J Diabetes Metab Disord (2013) 1.43
Factors associated with mortality in patients with drug-susceptible pulmonary tuberculosis. BMC Infect Dis (2011) 1.38
Survival analysis of adult tuberculosis disease. PLoS One (2014) 1.38
Impact of diabetes and smoking on mortality in tuberculosis. PLoS One (2013) 1.36
Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. Thorax (2006) 1.33
Deaths among tuberculosis cases in Shanghai, China: who is at risk? BMC Infect Dis (2009) 1.33
Immunological mechanisms contributing to the double burden of diabetes and intracellular bacterial infections. Immunology (2015) 1.17
Tuberculosis and its incidence, special nature, and relationship with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2007) 1.14
Mortality before or during treatment among tuberculosis patients in North Carolina, 1993-2003. Int J Tuberc Lung Dis (2011) 1.12
Tuberculosis treatment adherence and fatality in Spain. Respir Res (2009) 1.09
The influence of diabetes, glycemic control, and diabetes-related comorbidities on pulmonary tuberculosis. PLoS One (2015) 1.05
Association between smoking and latent tuberculosis in the U.S. population: an analysis of the National Health and Nutrition Examination Survey. PLoS One (2012) 1.01
HIV-specific health care utilization and mortality among tuberculosis/HIV coinfected persons. AIDS Patient Care STDS (2009) 1.01
Factors associated with mortality in hospitalized patients with newly diagnosed tuberculosis. Lung (2010) 0.99
Tuberculosis mortality: patient characteristics and causes. BMC Infect Dis (2014) 0.94
Risk factors for death during pulmonary tuberculosis treatment in Korea: a multicenter retrospective cohort study. J Korean Med Sci (2014) 0.92
Diabetes mellitus and risk of all-cause mortality among patients with tuberculosis in the state of Georgia, 2009-2012. Ann Epidemiol (2014) 0.87
Malnutrition and pulmonary tuberculosis. Clin Infect Dis (2002) 0.86
Understanding pharmacokinetics to improve tuberculosis treatment outcome. Expert Opin Drug Metab Toxicol (2014) 0.82
Is early tuberculosis death associated with increased tuberculosis transmission? PLoS One (2015) 0.79
Changes in glycosylated haemoglobin and treatment outcomes in patients with tuberculosis in Iran: a cohort study. J Diabetes Metab Disord (2014) 0.79
Survival and Predictors of Death after Successful Treatment among Smear Positive Tuberculosis: A Cohort Study. Int J Prev Med (2014) 0.78
Long-term mortality in patients with pulmonary and extrapulmonary tuberculosis: a Danish nationwide cohort study. Clin Epidemiol (2014) 0.75
Estimation of Ten-Year Survival of Patients with Pulmonary Tuberculosis Based on the Competing Risks Model in Iran. Tanaffos (2016) 0.75
The effect of tuberculosis on the mortality of cirrhotic patients: a population-based 3-year follow-up study. Medicine (Baltimore) (2014) 0.75
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med (2003) 14.40
Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat. Lancet Infect Dis (2005) 6.85
Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med (2007) 6.26
Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med (2011) 6.14
The lifetime cost of current human immunodeficiency virus care in the United States. Med Care (2006) 5.87
Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis (2009) 5.75
Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet (2009) 5.30
Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr (2006) 4.81
Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med (2003) 4.67
Latent Mycobacterium tuberculosis infection. N Engl J Med (2015) 4.62
Immune status at presentation to care did not improve among antiretroviral-naive persons from 1990 to 2006. Clin Infect Dis (2007) 4.10
The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS (2007) 4.09
A trial of mass isoniazid preventive therapy for tuberculosis control. N Engl J Med (2014) 4.07
Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. J Acquir Immune Defic Syndr (2005) 3.92
Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis (2010) 3.72
A postgenomic method for predicting essential genes at subsaturation levels of mutagenesis: application to Mycobacterium tuberculosis. Proc Natl Acad Sci U S A (2003) 3.70
Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis (2003) 3.63
Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med (2009) 3.57
Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol (2007) 3.46
New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med (2011) 3.46
Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med (2004) 3.45
Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS (2002) 3.45
Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Med (2012) 3.44
Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa. J Acquir Immune Defic Syndr (2009) 3.41
Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis (2007) 3.39
Racial and sex disparities in life expectancy losses among HIV-infected persons in the united states: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin Infect Dis (2009) 3.30
Is the quality of the patient-provider relationship associated with better adherence and health outcomes for patients with HIV? J Gen Intern Med (2006) 3.25
Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis (2003) 3.24
Extensively drug-resistant tuberculosis. Lancet Infect Dis (2008) 3.21
Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med (2006) 3.20
Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS (2007) 3.19
Hospital and outpatient health services utilization among HIV-infected adults in care 2000-2002. Med Care (2005) 3.19
Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: a tale of two races. J Infect Dis (2008) 3.17
Hepatitis C and progression of HIV disease. JAMA (2002) 3.15
Cohort profile: the Centers for AIDS Research Network of Integrated Clinical Systems. Int J Epidemiol (2008) 3.14
Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS (2009) 3.06
Evaluation of a whole-blood interferon-gamma release assay for the detection of Mycobacterium tuberculosis infection in 2 study populations. Clin Infect Dis (2002) 3.06
Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. Clin Infect Dis (2005) 3.00
Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial. Lancet Infect Dis (2013) 2.95
Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis (2005) 2.92
Substance abuse and psychiatric disorders in HIV-positive patients: epidemiology and impact on antiretroviral therapy. Drugs (2006) 2.89
Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med (2007) 2.86
Diagnostic accuracy of a urine lipoarabinomannan test for tuberculosis in hospitalized patients in a High HIV prevalence setting. J Acquir Immune Defic Syndr (2009) 2.81
Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy. Am J Epidemiol (2006) 2.81
Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr (2013) 2.78
Hazardous alcohol use: a risk factor for non-adherence and lack of suppression in HIV infection. J Acquir Immune Defic Syndr (2006) 2.78
Treatment supporter to improve adherence to antiretroviral therapy in HIV-infected South African adults. A qualitative study. J Acquir Immune Defic Syndr (2006) 2.77
Reduced immunopathology and mortality despite tissue persistence in a Mycobacterium tuberculosis mutant lacking alternative sigma factor, SigH. Proc Natl Acad Sci U S A (2002) 2.76
Risk of non-AIDS-related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4+ counts greater than 200 cells/mm3. J Acquir Immune Defic Syndr (2007) 2.73
Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology (2002) 2.71
Total lymphocyte count and hemoglobin combined in an algorithm to initiate the use of highly active antiretroviral therapy in resource-limited settings. AIDS (2003) 2.52
Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis (2012) 2.50
Elevated incidence of lung cancer among HIV-infected individuals. J Clin Oncol (2006) 2.46
Dormancy phenotype displayed by extracellular Mycobacterium tuberculosis within artificial granulomas in mice. J Exp Med (2004) 2.46
Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy. Lancet Infect Dis (2004) 2.44
Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS (2005) 2.34
Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis (2008) 2.32
Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. AIDS (2008) 2.25
Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. Clin Infect Dis (2009) 2.25
Antiretroviral medication errors remain high but are quickly corrected among hospitalized HIV-infected adults. Clin Infect Dis (2012) 2.24
Causes of death in hospitalized adults with a premortem diagnosis of tuberculosis: an autopsy study. AIDS (2007) 2.23
From magic bullets back to the magic mountain: the rise of extensively drug-resistant tuberculosis. Nat Med (2007) 2.23
Confronting multidrug-resistant tuberculosis. N Engl J Med (2012) 2.22
Renal function with use of a tenofovir-containing initial antiretroviral regimen. AIDS (2009) 2.22
Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis. Am J Respir Crit Care Med (2005) 2.21
Performance of the microscopic observation drug susceptibility assay in drug susceptibility testing for Mycobacterium tuberculosis. J Clin Microbiol (2002) 2.21
Establishment, retention, and loss to follow-up in outpatient HIV care. J Acquir Immune Defic Syndr (2012) 2.19
Noninvasive pulmonary [18F]-2-fluoro-deoxy-D-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment. Antimicrob Agents Chemother (2009) 2.18
Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother (2006) 2.18
U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Ann Intern Med (2012) 2.18
Contemporary costs of HIV healthcare in the HAART era. AIDS (2010) 2.16
Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals. AIDS (2008) 2.14
Cyclic AMP intoxication of macrophages by a Mycobacterium tuberculosis adenylate cyclase. Nature (2009) 2.13
Statistical design of THRio: a phased implementation clinic-randomized study of a tuberculosis preventive therapy intervention. Clin Trials (2007) 2.12
Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. AIDS (2004) 2.11
Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups. Clin Infect Dis (2006) 2.08
Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis (2009) 2.05
Impact of enhanced tuberculosis diagnosis in South Africa: a mathematical model of expanded culture and drug susceptibility testing. Proc Natl Acad Sci U S A (2008) 2.03
HIV infection-related tuberculosis: clinical manifestations and treatment. Clin Infect Dis (2010) 2.02
Comparing different measures of retention in outpatient HIV care. AIDS (2012) 1.98
Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions. J Infect Dis (2011) 1.96
Mycobacterium tuberculosis ECF sigma factor sigC is required for lethality in mice and for the conditional expression of a defined gene set. Mol Microbiol (2004) 1.96
Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era. J Natl Cancer Inst (2013) 1.96
Lumbar puncture in HIV-infected patients with syphilis and no neurologic symptoms. Clin Infect Dis (2009) 1.95
Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009. Clin Infect Dis (2013) 1.94
Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung. Clin Lung Cancer (2012) 1.93